Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Clinical Autonomic Research
Published in: Clinical Autonomic Research 1/2018

01-02-2018 | Review

Urological dysfunction in synucleinopathies: epidemiology, pathophysiology and management

Authors: Ryuji Sakakibara, Fuyuki Tateno, Tatsuya Yamamoto, Tomoyuki Uchiyama, Tomonori Yamanishi

Published in: Clinical Autonomic Research | Issue 1/2018

Login to get access

Abstract

Objective

Parkinson’s disease (PD) and multiple system atrophy (MSA) are major neurogenerative diseases characterized pathologically by abnormal alpha-synuclein aggregation. PD and MSA are clinically characterized by motor disorder and bladder dysfunction (mainly urinary urgency and frequency, also called overactive bladder). However, few literatures are available concerning bladder dysfunction in PD or MSA.

Method

A systematic review.

Results

The bladder dysfunction in MSA is more severe than that in PD for large post-void residual or urinary retention. These bladder dysfunctions presumably reflect the different nervous system pathologies. Overactive bladder in PD reflects lesions in the brain, e.g., in the prefrontal-nigrostriatal D1 dopaminergic bladder-inhibitory pathway. Overactive bladder in MSA reflects lesions similar to PD and the cerebellum (bladder-inhibitory), and the urinary retention in MSA presumably reflects lesions in the pontine micturition center and the sacral intermediolateral nucleus of the spinal cord (bladder-facilitatory). Bladder dysfunction not only impairs an individual’s quality of life, it can also cause emergency hospitalizations due to acute retention and early institutionalization. Anticholinergics are the first-line treatment for bladder dysfunction in PD and MSA patients, but care should be taken for the management of bladder dysfunction—particularly in MSA patients due to the high prevalence of difficult emptying, which needs clean, intermittent catheterization.

Conclusions

This review summarizes the epidemiology, pathophysiology, and management of bladder dysfunction in individuals with PD or MSA.
Literature
1.
Goedert M, Jakes R, Spillantini MG (2017) The synucleinopathies: twenty years on. J Parkinsons Dis 7:S53–S71PubMed
2.
Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30:1591–1601CrossRefPubMed
3.
Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, Wood NW, Colosimo C, Dürr A, Fowler CJ, Kaufmann H, Klockgether T, Lees A, Poewe W, Quinn N, Revesz T, Robertson D, Sandroni P, Seppi K, Vidailhet M (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71:670–676CrossRefPubMedPubMedCentral
4.
Kikuchi A, Takeda A, Okamura N, Tashiro M, Hasegawa T, Furumoto S et al (2010) In vivo visualization of alpha-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy] benzoxazole positron emission tomography in multiple system atrophy. Brain 133:1772–1778CrossRefPubMed
5.
Tateno F, Sakakibara R, Ogata T, Kishi M, Tsuyusaki Y, Takahashi O, Sugiyama M, Tateno A (2015) Lower urinary tract function in dementia with Lewy bodies (DLB). Mov Disord 30:411–415CrossRefPubMed
6.
Cooper CA, Chahine LM (2016) Biomarkers in prodromal Parkinson disease: a qualitative review. J Int Neuropsychol Soc 22:956–967CrossRefPubMed
7.
McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, Consortium on DLB et al (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65:1863–1872CrossRefPubMed
8.
Stanzani-Maserati M, Gallassi R, Calandra-Buonaura G, Alessandria M, Oppi F, Poda R, Sambati L, Provini F, Cortelli P (2014) Cognitive and sleep features of multiple system atrophy: review and prospective study. Eur Neurol 72:349–359CrossRefPubMed
9.
Ozawa T, Revesz T, Paviour D, Lees AJ, Quinn N, Tada M, Kakita A, Onodera O, Wakabayashi K, Takahashi H, Nishizawa M, Holton JL (2012) Difference in MSA phenotype distribution between populations: genetics or environment? J Parkinsons Dis 2:7–18PubMed
10.
Sakakibara R, Tateno F, Nagao T, Yamamoto T, Uchiyama T, Yamanishi T, Yano M, Kishi M, Tsuyusaki Y, Aiba Y (2014) Bladder function of patients with Parkinson’s disease. Int J Urol 21:638–646CrossRefPubMed
11.
Ogawa T, Sakakibara R, Kuno S, Ishizuka O, Kitta T, Yoshimura N (2017) Prevalence and treatment of LUTS in patients with Parkinson disease or multiple system atrophy. Nat Rev Urol 14:79–89CrossRefPubMed
12.
Sakakibara R (2015) Lower urinary tract dysfunction in patients with brain lesions. Handb Clin Neurol 130:269–287CrossRefPubMed
13.
Sakakibara R, Uchiyama T, Yamanishi T, Kishi M (2009) Sphincter EMG as a diagnostic tool in autonomic disorders. Clin Auton Res 19:20–31CrossRefPubMed
14.
Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A, Standardisation Sub-committee of the International Continence Society (2002) The standardization of terminology of lower urinary tract function: report from the standardization sub-committee of the International Continence Society. Neurourol Urodyn 21:167–178CrossRefPubMed
15.
Sakakibara R, Panicker J, Fowler CJ, Tateno F, Kishi M, Tsuyusaki Y, Yamanishi T, Uchiyama T, Yamamoto T, Yano M (2014) Is overactive bladder a brain disease? The pathophysiological role of cerebral white matter in the elderly. Int J Urol 21:33–38CrossRefPubMed
16.
Sakakibara R, Shinotoh H, Uchiyama T, Sakuma M, Kashiwado M, Yoshiyama M, Hattori T (2001) Questionnaire-based assessment of pelvic organ dysfunction in Parkinson’s disease. Auton Neurosci 92:76–85CrossRefPubMed
17.
Araki I, Kuno S (2000) Assessment of voiding dysfunction in Parkinson’s disease by the international prostate symptom score. J Neurol Neurosurg Psychiatry 68:429–433CrossRefPubMedPubMedCentral
18.
Takahashi O, Sakakibara R, Tateno F, Kishi M, Tsuyusaki Y, Aiba Y, Yano H, Sugiyama M, Yamamoto T, Yamanishi T, Uchiyama T, Shibata C, Tomaru T (2014) Overactive bladder may precede motor disorder in Parkinson’s disease: a urodynamic study. Parkinsonism Relat Disord 20:1030–1032CrossRefPubMed
19.
Sakakibara R, Hattori T, Uchiyama T, Yamanishi T (2001) Videourodynamic and sphincter motor unit potential analyses in Parkinson’s disease and multiple system atrophy. J Neurol Neurosurg Psychiatry 71:600–606CrossRefPubMedPubMedCentral
20.
Terayama K, Sakakibara R, Ogawa A, Haruta H, Akiba T, Nagao T, Takahashi O, Sugiyama M, Tateno A, Tateno F, Yano M, Kishi M, Tsuyusaki Y, Uchiyama T, Yamamoto T (2012) Weak detrusor contractility correlates with motor disorders in Parkinson’s disease. Mov Disord 27:1775–1780CrossRefPubMed
21.
Liu Z, Uchiyama T, Sakakibara R, Yamamoto T (2015) Underactive and overactive bladders are related to motor function and quality of life in Parkinson’s disease. Int Urol Nephrol 47:751–757CrossRefPubMed
22.
Yamamoto T, Sakakibara R, Uchiyama T, Liu Z, Ito T, Awa Y, Yamanishi T, Hattori T (2006) Neurological diseases that cause detrusor hyperactivity with impaired contractile function. Neurourol Urodyn 25:356–360CrossRefPubMed
23.
Tsunoyama K, Sakakibara R, Yamaguchi C, Uchiyama T, Yamamoto T, Yamanishi T, Takahashi O, Sugiyama M, Kishi M, Ogawa E (2011) Pathogenesis of reduced or increased bladder sensation. Neurourol Urodyn 30:339–343CrossRefPubMed
24.
25.
Sakakibara R, Nakazawa K, Shiba K, Nakajima Y, Uchiyama T, Yoshiyama M, Yamanishi T, Hattori T (2002) Firing patterns of micturition-related neurons in the pontine storage center in cats. Auton Neurosci 99:24–30CrossRefPubMed
26.
Fowler CJ, Griffiths DJ (2010) A decade of functional brain imaging applied to bladder control. Neurourol Urodyn 29:49–55PubMed
27.
Sakakibara R, Tsunoyama K, Takahashi O, Sugiyama M, Kishi M, Ogawa E, Uchiyama T, Yamamoto T, Yamanishi T, Awa Y, Yamaguchi C (2010) Real-time measurement of oxyhemoglobin concentration changes in the frontal micturition area: an fNIRS study. Neurourol Urodyn 29:757–764CrossRefPubMed
28.
Sakakibara R, Nakazawa K, Uchiyama T, Yoshiyama M, Yamanishi T, Hattori T (2002) Micturition-related electrophysiological properties in the substantia nigra pars compacta and the ventral tegmental area in cats. Auton Neurosci 102:30–38CrossRefPubMed
29.
Yamamoto T, Sakakibara R, Nakazawa K, Uchiyama T, Shimizu E, Hattori T (2009) Effects of electrical stimulation of the striatum on bladder activity in cats. Neurourol Urodyn 28:549–554CrossRefPubMed
30.
Sakakibara R, Nakazawa K, Uchiyama T, Yoshiyama M, Yamanishi T, Hattori T (2003) Effects of subthalamic nucleus stimulation on the micturation reflex in cats. Neuroscience 120:871–875CrossRefPubMed
31.
Kitta T, Chancellor MB, de Groat WC, Kuno S, Nonomura K, Yoshimura N (2012) Suppression of bladder overactivity by adenosine A2A receptor antagonist in a rat model of Parkinson disease. J Urol 187:1890–1897CrossRefPubMed
32.
Kitta T, Kakizaki H, Furuno T, Moriya K, Tanaka H, Shiga T, Tamaki N, Yabe I, Sasaki H, Nonomura K (2006) Brain activation during detrusor overactivity in patients with Parkinson’s disease: a positron emission tomography study. J Urol 175:994–998CrossRefPubMed
33.
Yamamoto T, Sakakibara R, Nakazawa K, Uchiyama T, Shimizu E, Hattori T, Kuwabara S (2010) Neuronal activities of forebrain structures with respect to bladder contraction in cats. Neurosci Lett 473:42–47CrossRefPubMed
34.
Kitta T, Chancellor MB, de Groat WC, Shinohara N, Yoshimura N (2016) Role of the anterior cingulate cortex in the control of micturition reflex in a rat model of Parkinson’s disease. J Urol 195:1613–1620CrossRefPubMed
35.
Uchiyama T, Sakakibara R, Yoshiyama M, Yamamoto T, Ito T, Liu Z, Yamaguchi C, Awa Y, Yano HM, Yanagisawa M, Yamanishi T, Hattori T, Kuwabara S (2009) Biphasic effect of apomorphine, an anti-parkinsonian drug, on bladder function in rats. Neuroscience 162:1333–1338CrossRefPubMed
36.
Brusa L, Petta F, Pisani A, Moschella V, Iani C, Stanzione P, Miano R, Finazzi-Agrò E (2007) Acute vs chronic effects of l-dopa on bladder function in patients with mild Parkinson disease. Neurology 68:1455–1459CrossRefPubMed
37.
Uchiyama T, Sakakibara R, Yamamoto T, Ito T, Yamaguchi C, Awa Y, Yano M, Yanagisawa M, Kobayashi M, Higuchi Y, Ichikawa T, Yamanishi T, Hattori T, Kuwabara S (2009) Comparing bromocriptine effects with levodopa effects on bladder function in Parkinson’s disease. Mov Disord 24:2386–2390PubMed
38.
Brusa L, Musco S, Bernardi G, Iani C, Pierantozzi M, Stanzione P, Stefani A, Finazzi Agro’ E (2014) Rasagiline effect on bladder disturbances in early mild Parkinson’s disease patients. Parkinsonism Relat Disord 20:931–932CrossRefPubMed
39.
Zesiewicz TA, Evatt M, Vaughan CP, Jahan I, Singer C, Ordorica R, Salemi JL, Shaw JD, Sullivan KL, Non-Motor Working Group of the Parkinson Study Group (PSG) (2015) Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson’s disease. Parkinsonism Relat Disord 21:514–520CrossRefPubMed
40.
Sakakibara R, Uchiyama T, Yoshiyama M, Yamanishi T, Hattori T (2005) Preliminary communication: urodynamic assessment of donepezil hydrochloride in patients with Alzheimer’s disease. Neurourol Urodyn 24:273–275CrossRefPubMed
41.
42.
Sakakibara R, Hamano H, Yagi H (2014) Cognitive safety and overall tolerability of imidafenacin in clinical use: a long-term, open-label, post-marketing surveillance study. Low Urin Tract Symptoms 6:138–144CrossRefPubMed
43.
Sakakibara R, Ogata T, Uchiyama T, Kishi M, Ogawa E, Isaka S, Yuasa J, Yamamoto T, Ito T, Yamanishi T, Awa Y, Yamaguchi C, Takahashi O (2009) How to manage overactive bladder in elderly individuals with dementia? A combined use of donepezil, a central AChE inhibitor, and propiverine, a peripheral muscarine receptor antagonist. J Am Geriatr Soc 57:1515–1517CrossRefPubMed
44.
Igawa Y, Michel MC (2013) Pharmacological profile of β3-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome. Naunyn Schmiedebergs Arch Pharmacol 386:177–183CrossRefPubMed
45.
Vaughan CP, Juncos JL, Burgio KL, Goode PS, Wolf RA, Johnson TM 2nd (2011) Behavioral therapy to treat urinary incontinence in Parkinson disease. Neurology 76:1631–1634CrossRefPubMed
46.
Ito T, Sakakibara R, Nakazawa K, Uchiyama T, Yamamoto T, Liu Z, Shimizu E, Hattori T (2006) Effects of electrical stimulation of the raphe area on the micturition reflex in cats. Neuroscience 142:1273–1280CrossRefPubMed
47.
Sakakibara R, Ito T, Uchiyama T, Awa Y, Yamaguchi C, Hattori T (2008) Effects of milnacipran and paroxetine on overactive bladder due to neurologic diseases: a urodynamic assessment. Urol Int 81:335–339CrossRefPubMed
48.
Suchowersky O, Furtado S, Rohs G (1995) Beneficial effect of intranasal desmopressin for nocturnal polyuria in Parkinson’s disease. Mov Disord 10:337–340CrossRefPubMed
49.
Finazzi-Agro E, Peppe A, d’Amico A, Petta F, Mazzone P, Stanzione P, Micali F, Caltagirone C (2003) Effects of subthalamic nucleus stimulation on urodynamic findings in patients with Parkinson’s disease. J Urol 169:1388–1391CrossRefPubMed
50.
Herzog J, Weiss PH, Assmus A, Wefer B, Seif C, Braun PM, Pinsker MO, Herzog H, Volkmann J, Deuschl G, Fink GR (2008) Improved sensory gating of urinary bladder afferents in Parkinson’s disease following subthalamic stimulation. Brain 131:132–145CrossRefPubMed
51.
Kabay SC, Kabay S, Yucel M, Ozden H (2009) Acute urodynamic effects of percutaneous posterior tibial nerve stimulation on neurogenic detrusor overactivity in patients with Parkinson’s disease. Neurourol Urodyn 28:62–67CrossRefPubMed
52.
Brusa L, Finazzi Agrò E, Petta F, Sciobica F, Torriero S, Lo Gerfo E, Iani C, Stanzione P, Koch G (2009) Effects of inhibitory rTMS on bladder function in Parkinson’s disease patients. Mov Disord 24:445–448CrossRefPubMed
53.
Kulaksizoglu H, Parman Y (2010) Use of botulinim toxin-A for the treatment of overactive bladder symptoms in patients with Parkinsons’s disease. Parkinsonism Relat Disord 16:531–534CrossRefPubMed
54.
Soler R, Füllhase C, Hanson A, Campeau L, Santos C, Andersson KE (2012) Stem cell therapy ameliorates bladder dysfunction in an animal model of Parkinson disease. J Urol 187:1491–1497CrossRefPubMed
55.
Sakakibara R, Panicker J, Finazzi-Agro E, Iacovelli V, Bruschini H, Parkinson’s Disease Subcomittee, The Neurourology Promotion Committee in The International Continence Society (2016) A guideline for the management of bladder dysfunction in Parkinson’s disease and other gait disorders. Neurourol Urodyn 35:551–563CrossRefPubMed
56.
Yamamoto T, Sakakibara R, Uchiyama T, Liu Z, Ito T, Awa Y, Yamanishi T, Hattori T (2009) Questionnaire-based assessment of pelvic organ dysfunction in multiple system atrophy. Mov Disord 24:972–978CrossRefPubMed
57.
Yamamoto T, Sakakibara R, Uchiyama T, Yamaguchi C, Nomura F, Ito T, Yanagisawa M, Yano M, Awa Y, Yamanishi T, Hattori T, Kuwabara S (2011) Pelvic organ dysfunction is more prevalent and severe in MSA-P compared to Parkinson’s disease. Neurourol Urodyn 30:102–107CrossRefPubMed
58.
Sakakibara R, Hattori T, Uchiyama T, Kita K, Asahina M, Suzuki A, Yamanishi T (2000) Urinary dysfunction and orthostatic hypotension in multiple system atrophy: which is the more common and earlier manifestation? J Neurol Neurosurg Psychiatry 68:65–69CrossRefPubMedPubMedCentral
59.
Gilman S, May SJ, Shults CW, Tanner CM, Kukull W, Lee VM, Masliah E, Low P, Sandroni P, Trojanowski JQ, Ozelius L, Foroud T, North American Multiple System Atrophy Study Group (2005) The North American Multiple System Atrophy Study Group. J Neural Transm 112:1687–1694CrossRefPubMed
60.
Cykowski MD, Coon EA, Powell SZ, Jenkins SM, Benarroch EE, Low PA, Schmeichel AM, Parisi JE (2015) Expanding the spectrum of neuronal pathology in multiple system atrophy. Brain 138:2293–2309CrossRefPubMedPubMedCentral
61.
Sakakibara R, Uchida Y, Uchiyama T, Yamanishi T, Hattori T (2004) Reduced cerebellar vermis activation in response to micturition in multiple system atrophy: 99mTc-labeled ECD SPECT study. Eur J Neurol 11:705–708CrossRefPubMed
62.
63.
Ito T, Sakakibara R, Yasuda K, Yamamoto T, Uchiyama T, Liu Z, Yamanishi T, Awa Y, Yamamoto K, Hattori T (2006) Incomplete emptying and urinary retention in multiple-system atrophy: when does it occur and how do we manage it? Mov Disord 21:816–823CrossRefPubMed
64.
Yamamoto T, Sakakibara R, Uchiyama T, Yamaguchi C, Nomura F, Ito T, Yanagisawa M, Yano M, Awa Y, Yamanishi T, Hattori T, Kuwabara S (2012) Receiver operating characteristic analysis of sphincter electromyography for parkinsonian syndrome. Neurourol Urodyn 31:1128–1134CrossRefPubMed
65.
Paviour DC, Williams DC, Fowler CJ, Quinn NP, Lees AJ (2005) Is sphincter electromyography a helpful investigation in the diagnosis of multiple system atrophy? A retrospective study with pathological diagnosis. Mov Disord 20:1425–1430CrossRefPubMed
66.
Mashidori T, Yamanishi T, Yoshida K, Sakakibara R, Sakurai K, Hirata K (2007) Continuous urinary incontinence presenting as the initial symptoms demonstrating acontractile detrusor and intrinsic sphincter deficiency in multiple system atrophy. Int J Urol 14:972–974CrossRefPubMed
67.
Takahashi O, Sakakibara R, Tsunoyama K, Tateno F, Yano M, Sugiyama M, Uchiyama T, Yamamoto T, Awa Y, Yamaguchi C, Yamanishi T, Kishi M, Tsuyuzaki Y (2012) Do sacral/peripheral lesions contribute to detrusor-sphincter dyssynergia? LUTS 4:126–129PubMed
68.
Pramstaller PP, Wenning GK, Smith SJM, Beck RO, Quinn NP, Fowler CJ (1995) Nerve conduction studies, skeletal muscle EMG, and sphincter EMG in multiple system atrophy. J Neurol Neurosurg Psychiatry 580:618–621CrossRef
69.
Yamamoto T, Sakakibara R, Uchiyama T, Yamaguchi C, Ohno S, Nomura F, Yanagisawa M, Hattori T, Kuwabara S (2014) Time-dependent changes and gender differences in urinary dysfunction in patients with multiple system atrophy. Neurourol Urodyn 33:516–523CrossRefPubMed
70.
Mathias CJ, Fosbraey P, DaCosta DF, Thornley A, Bannister R (1986) The effect of desmopressin on nocturnal polyuria, overnight weight loss, and morning postural hypotension in patients with autonomic failure. BMJ 293:353–356CrossRefPubMedPubMedCentral
71.
Sakakibara R, Matsuda S, Uchiyama T, Yoshiyama M, Yamanishi T, Hattori T (2003) The effect of intranasal desmopressin on nocturnal waking in urination in multiple system atrophy patients with nocturnal polyuria. Clin Auton Res 13:106–108CrossRefPubMed
72.
Sakakibara R, Murakami E, Katagiri A, Hayakawa S, Uchiyama T, Yamamoto T, Hattori T (2007) Moxibustion, an alternative therapy, ameliorated disturbed circadian rhythm of plasma arginine vasopressin and urine output in multiple system atrophy. Intern Med 46:1015–1018CrossRefPubMed
73.
Sakakibara R, Hattori T, Uchiyama T, Suenaga T, Takahashi H, Yamanishi T, Egoshi K, Sekita N (2000) Are alpha-blockers involved in lower urinary tract dysfunction in multiple system atrophy? A comparison of prazosin and moxisylyte. J Auton Nerv Syst 79:191–195CrossRefPubMed
74.
Sakakibara R, Uchiyama T, Asahina M, Yoshiyama M, Yamanishi T, Hattori T (2003) Amezinium metilsulfate, a sympathomimetic agent, may increase the risk of urinary retention in multiple system atrophy. Clin Auton Res 13:51–53CrossRefPubMed
75.
Yamamoto T, Sakakibara R, Yamanaka Y, Uchiyama T, Asahina M, Liu Z, Ito T, Koyama Y, Awa Y, Yamamoto K, Kinou M, Hattori T (2006) Pyridostigmine in autonomic failure: can we treat postural hypotension and bladder dysfunction with one drug? Clin Auton Res 16:296–298CrossRefPubMed
76.
Uchiyama T, Sakakibara R, Asahina M, Yamanishi T, Hattori T (2005) Post-micturitional hypotension in patients with multiple system atrophy. J Neurol Neurosurg Psychiatry 76:186–190CrossRefPubMedPubMedCentral
77.
78.
Coon EA, Sletten DM, Suarez MD, Mandrekar JN, Ahlskog JE, Bower JH, Matsumoto JY, Silber MH, Benarroch EE, Fealey RD, Sandroni P, Low PA, Singer W (2015) Clinical features and autonomic testing predict survival in multiple system atrophy. Brain 138:3623–3631CrossRefPubMedPubMedCentral
Metadata
Title
Urological dysfunction in synucleinopathies: epidemiology, pathophysiology and management
Authors
Ryuji Sakakibara
Fuyuki Tateno
Tatsuya Yamamoto
Tomoyuki Uchiyama
Tomonori Yamanishi
Publication date
01-02-2018
Publisher
Springer Berlin Heidelberg
Published in
Clinical Autonomic Research / Issue 1/2018
Print ISSN: 0959-9851
Electronic ISSN: 1619-1560
DOI
https://doi.org/10.1007/s10286-017-0480-0

Other articles of this Issue 1/2018

Clinical Autonomic Research 1/2018 Go to the issue

Editorial

The sacral autonomic outflow: against premature oversimplification

Review

The physical examination as a window into autonomic disorders

Letter to the Editor

Metoprolol, propranolol, carvedilol, or labetalol for patients with Takotsubo syndrome?

Review

The “sacral parasympathetic”: ontogeny and anatomy of a myth

Correction

Correction to: Electrocardiogram-based predictors for arrhythmia after spinal cord injury

Letter to the Editor

Neurogenic dysphagia with undigested macaroni and megaesophagus in familial dysautonomia